According to a new report from Technavio, the global market for blood gas and electrolyte analyzers is expected to grow at a CAGR of over 6% from 2014-2019. The report also emphasizes a shift from benchtop analyzers to portable analyzers by end-users because of the latter’s efficiency and accurate results.
Blood gas analysis or arterial blood gas (ABG) analysis is often recommended to detect lung disease, kidney disease, metabolic disease, head or neck injuries that affect breathing. The tests may be ordered along with electrolytes to detect electrolyte imbalance, glucose to measure blood sugar concentrations, and BUN and creatinine tests to assess kidney function.
Blood gas analyzers measure:
- The concentration of hydrogen ions to evaluate acidity level
- The pressure of carbon dioxide and oxygen
- Electrolytes such as sodium, calcium, chloride ions, and bicarbonate ions
Abnormal results of any of the blood gas components indicate problems such as: the person is not getting enough oxygen, is not getting rid of enough carbon dioxide, or has problems with kidney function.
Technavio reports that rapid innovation plays a key role in the development of products and equipment in the healthcare industry as improved operational technologies are expected to reduce overall costs and allow hassle-free use of the equipment. While the growing aging population is one of the major factors that fuels the growth of the market, replacement and maintenance are reported to be the factors restricting its growth.
Vice President of Technavio Faisal Ghaus says, “With the introduction of point-of-care, the global blood gas and electrolyte analyzers market has witnessed significant changes in term of usage and investment by end-users. For instance, manufacturers of POC analyzers frequently update their products with new features, thus making the market competitive.”
The report identifies the key vendors in the market as Medica, Nova Biomedical, Roche, Samsung Medison and Siemens Healthcare.